Stay on top of the latest developments in anti-obesity treatments, with comprehensive analysis and forecasts on the clinical, commercial, and epidemiological landscapes.
Largely thanks to the introduction of GLP-1 agonists, the obesity market has skyrocketed in the past few years, due to surpass $80 Bn USD in less than a decade. This dynamic market is continually expanding and being driven by factors beyond medical need, leading to both opportunities as well as questions around demand, pricing, eligibility, etc.
Airfinity’s Obesity Market Intelligence Solution combines data, technology, and expertise to help you stay ahead of critical developments and inform your ongoing clinical and commercial strategies. We work with you to understand and predict the impact of any development (existing or potential), ultimately saving you time, resources, and money.
The first ever obesity market platform provides pipeline, competitor, disease, and commercial insights, updated and accessible 24/7 with extensive filters.
High impact analyses on critical Obesity topics by expert analysts, e.g. costs to prevent comorbidity and major CVRM events comparing AOMs to bariatric surgery & CV drugs.
Real time analysis of critical news such as key product launch or pivotal results delivered directly to your inbox and available via the platform.
Get direct access to Airfinity science and market experts, including an optional monthly briefing for your entire team.
Wegovy costs $1.3m to prevent one heart attack, stroke, or cardiovascular death
Anti-obesity drug rush: Industry 'testing' nearly 190 candidates (es)
Weight loss injections could prevent 300,000 heart failures in the US by 2030, forecasts Airfinity
Airfinity forecasts the severely obese population with metabolic syndrome in the US to grow 50% by 2030 from 26 million to 39.1 million people.
View All →
Fill out this short form to request your free demo of Airfinity’s Obesity Market Intelligence Solution.